Tolerability profile of paliperidone palmitate formulations: A pharmacovigilance analysis of the EUDRAVigilance database.

For PP-related ICSRs an initially steady trend was followed by a peak in 2018 ( n = 1,569) after the introduction of PP3M in the market and a decreasing trend afterwards ( Figure 1 ).

also in 47,180 other papers